



DAFTAR PUSTAKA

- Andayani, T.M., 2013. *Farmakoekonomi Prinsip Dan Metodologi*. Bursa Ilmu, Yogyakarta, Indonesia.
- Arteaga CL., 2001. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. *J Clin Oncol*;19:32S-40S.
- Battafarano, R.J., Piccirillo, J.F., Meyers, B.F., Hsu, H.-S., Guthrie, T.J., Cooper, J.D., dkk., 2002. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. *The Journal of Thoracic and Cardiovascular Surgery*, **123**: 280–287.
- Bootman, J., Townsend, R., dan McGhan, WF., 2005. *Principles of Pharmacoeconomics*, 3 rd Ed. ed. Harvey Whitney Books Company, Cincinnati.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., dan Jemal, A., 2018. 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries', *CA: A Cancer Journal for Clinicians*. URL: <https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21492> (diakses tanggal 2/9/2019).
- Burotto, M., Manasanch, E.E., Wilkerson, J., dan Fojo, T., 2015. Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials. *The Oncologist*, **20**: 400–410.
- Cardarella, S., Ortiz, T.M., Joshi, V.A., Butaney, M., Jackman, D.M., Kwiatkowski, D.J., dkk., 2012. The Introduction of Systematic Genomic Testing for Patients with Non-Small-Cell Lung Cancer. *Journal of Thoracic Oncology*, **7**: 1767–1774.
- Chiang, C.-J., Lo, W.-C., Yang, Y.-W., You, S.-L., Chen, C.-J., dan Lai, M.-S., 2016. Incidence and survival of adult cancer patients in Taiwan, 2002-2012. *Journal of the Formosan Medical Association = Taiwan Yi Zhi*, **115**: 1076–1088.
- Chouaid, C., Agulnik, J., Goker, E., Herder, G.J.M., Lester, J.F., Vansteenkiste, J., dkk., 2013. Health-Related Quality of Life and Utility in Patients with Advanced Non-Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting. *Journal of Thoracic Oncology*, **8**: 997–1003.



- Chouaid, C., Dujon, C., Do, P., Monnet, I., Madroszyk, A., Le Caer, H., dkk., 2014. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01). *Lung Cancer*, **86**: 170–173.
- Chouaid, C., Luciani, L., LeLay, K., Do, P., Bennouna, J., Perol, M., dkk., 2017. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers. *Journal of Thoracic Oncology*, **12**: 1496–1502.
- De Grève, J., Teugels, E., Geers, C., Decoster, L., Galdermans, D., De Mey, J., dkk., 2012. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. *Lung Cancer (Amsterdam, Netherlands)*, **76**: 123–127.
- Dela Cruz, C.S., Tanoue, L.T., dan Matthay, R.A., 2011. Lung Cancer: Epidemiology, Etiology, and Prevention. *Clinics in Chest Medicine*, **32**: 605–644.
- Devlin, N.J., Shah, K.K., Feng, Y., Mulhern, B., dan Hout, B. van, 2018. Valuing health-related quality of life: An EQ-5D-5L value set for England. *Health Economics*, **27**: 7–22.
- Dima, S., Chen, K.-H., Wang, K.-J., Wang, K.-M., dan Teng, N.-C., 2018. Effect of Comorbidity on Lung Cancer Diagnosis Timing and Mortality: A Nationwide Population-Based Cohort Study in Taiwan. *BioMed Research International*, **2018**: .
- Doyle, S., Lloyd, A., dan Walker, M., 2008. Health state utility scores in advanced non-small cell lung cancer. *Lung Cancer*, **62**: 374–380.
- Drummond F dan Torrance GW, 2005. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford University Press.
- Dungo, R.T. dan Keating, G.M., 2013. Afatinib: first global approval. *Drugs*, **73**: 1503–1515.
- Ellis, P.M., Coakley, N., Feld, R., Kuruvilla, S., dan Ung, Y.C., 2015. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. *Current Oncology*, **22**: 183.
- Endarti, D., Riewpaiboon, A., Thavorncharoensap, M., Praditsitthikorn, N., Hutubessy, R., dan Kristina, S.A., 2015. Evaluation of Health-Related Quality of Life among Patients with Cervical Cancer in Indonesia. *Asian Pacific Journal of Cancer Prevention*, **16**: 3345–3350.



- Ettinger, D.S., Wood, D.E., Aggarwal, C., Aisner, D.L., Akerley, W., Bauman, J.R., dkk., 2019. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. *Journal of the National Comprehensive Cancer Network: JNCCN*, **17**: 1464–1472.
- European Society for Medical Oncology (ESMO), 2017. *Non Small Cell Lung Cancer*. Kstorfin Medical Communications Switzerland
- Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., dan Parkin, D.M., 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *International Journal of Cancer*, **127**: 2893–2917.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., dkk., 2015. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer*, **136**: E359–E386.
- Hirsch, F.R. dan Bunn, P.A., 2009. EGFR testing in lung cancer is ready for prime time. *The Lancet. Oncology*, **10**: 432–433.
- Iachina, M., Green, A., dan Jakobsen, E., 2014. The direct and indirect impact of comorbidity on the survival of patients with non-small cell lung cancer: a combination of survival, staging and resection models with missing measurements in covariates. *BMJ open*, **4**: e003846.
- Ii, C.B.S. dan Jones, J.A., 2013. Palliative care for patients with locally advanced and metastatic non-small cell lung cancer. *Annals of Palliative Medicine*, **2**: 11.
- Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., dkk., 2009. First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy. *Journal of Clinical Oncology*, **27**: 1394–1400.
- Jang, R.W., Isogai, P.K., Mittmann, N., Bradbury, P.A., Shepherd, F.A., Feld, R., dkk., 2010. Derivation of Utility Values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer. *Journal of Thoracic Oncology*, **5**: 1953–1957.
- Jemal, A., Ward, E.M., Johnson, C.J., Cronin, K.A., Ma, J., Ryerson, A.B., dkk., 2017. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. *JNCI Journal of the National Cancer Institute*, **109**: .



- Jf, S. dan Sm, R., 2010. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. *Targeted Oncology*, **5**: 245–255.
- Kaisaeng, N., Harpe, S.E., dan Carroll, N.V., 2014. Out-of-Pocket Costs and Oral Cancer Medication Discontinuation in the Elderly. *Journal of Managed Care Pharmacy*, **20**: 669–675.
- Kang, S., Koh, E.-S., Vinod, S.K., dan Jalaludin, B., 2012. Cost analysis of lung cancer management in South Western Sydney. *Journal of Medical Imaging and Radiation Oncology*, **56**: 235–241.
- Kementerian Kesehatan RI., 2013. *Pedoman Penerapan Kajian Farmakoekonomi*. Direktorat Jenderal Bina Kefarmasian dan Alat Kesehatan, Jakarta.
- Kementerian Kesehatan RI., 2016. *Perubahan Kedua atas Keputusan Menteri Kesehatan No HK.02.02/MENKES/523/2015 tentang Formularium Nasional*. Menteri Kesehatan RI, Jakarta.
- Kementerian Kesehatan RI., 2017a. *Buku Panduan Penilaian Teknologi Kesehatan*. Komite Penilaian Teknologi Kesehatan, Jakarta.
- Kementerian Kesehatan RI., 2017b. *Pedoman Nasional Pelayanan Kedokteran Kanker Paru*. Komite Penanggulangan Kanker Nasional, Jakarta.
- Kementerian Kesehatan RI, 2018. Hasil Utama Riskesdas 2018. Badan Penelitian dan Pengembangan Kesehatan Jakarta
- Kim, S.T., Uhm, J.E., Lee, J., Sun, J., Sohn, I., Kim, S.W., dkk., 2012. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. *Lung Cancer*, **75**: 82–88.
- Kimura, M., Yasue, F., Usami, E., Kawachi, S., Iwai, M., Go, M., dkk., 2018. Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer. *Molecular and Clinical Oncology*, .
- Kishore, J., Goel, M., dan Khanna, P., 2010. Understanding Survival Analysis: Kaplan-Meier Estimate. *International Journal of Ayurveda Research*, **1**: 274.
- Koh, P.K., Faivre-Finn, C., Blackhall, F.H., dan De Ruysscher, D., 2012. Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy. *Cancer Treatment Reviews*, **38**: 626–640.



- Laird, B.J.A., Scott, A.C., Colvin, L.A., McKeon, A.-L., Murray, G.D., Fearon, K.C.H., dkk., 2011. Pain, Depression, and Fatigue as a Symptom Cluster in Advanced Cancer. *Journal of Pain and Symptom Management*, **42**: 1–11.
- Langer, C.J., 2013. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **31**: 3303–3306.
- Lee, V.H.F., Leung, D.K.C., Choy, T.-S., Lam, K.-O., Lam, P.-M., Leung, T.-W., dkk., 2016. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib. *BMC Cancer*, **16**: .
- Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L., dkk., 2008. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. *Oncogene*, **27**: 4702–4711.
- Li, H., 2014. Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Patients with/without EGFR-Mutation: Evidence Based on Recent Phase III Randomized Trials. *Medical Science Monitor*, **20**: 2666–2676.
- Liang, W., Wu, X., Fang, W., Zhao, Y., Yang, Y., Hu, Z., dkk., 2014. Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. *PLoS ONE*, **9**: e85245.
- Metro, G. dan Crinò, L., 2011. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. *Expert Review of Anticancer Therapy*, **11**: 673–682.
- Migliorino, M.R., Santo, A., Romano, G., Cortinovis, D., Galetta, D., Alabiso, O., dkk., 2017. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. *Journal of Cancer Research and Clinical Oncology*, **143**: 783–791.
- Mok, T.S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., dkk., 2009. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. *New England Journal of Medicine*, **361**: 947–957.
- Nafees, B., Stafford, M., Gavriel, S., Bhalla, S., dan Watkins, J., 2008. Health state utilities for non small cell lung cancer. *Health and Quality of Life Outcomes*, **6**: 84.



- Nazik, E., Nazik, H., Ozdemir, F., dan Soydan, S., 2014. Social Support and Quality of Life in Turkish Patients with Gynecologic Cancer. *Asian Pacific Journal of Cancer Prevention*, **15**: 3081–3086.
- Nelson, V., Ziehr, J., Agulnik, M., dan Johnson, M., 2013. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. *OncoTargets and Therapy*, **6**: 135–143.
- Nurul Aliyah S., Emmy H. Pranggono, Basti Andriyoko, 2016. Kanker paru: sebuah kajian singkat. Ina J CHEST Crit and Emerg Med | Vol. 3, No. 1 | Jan- Mar 2016
- Otsuka, T., Mori, M., Yano, Y., Uchida, J., Nishino, K., Kaji, R., dkk., 2015. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212). *Anticancer Research*, **35**: 3885–3891.
- Ou, S.-H.I., 2012. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. *Critical Reviews in Oncology/Hematology*, **83**: 407–421.
- Paik, P.K., Varghese, A.M., Sima, C.S., Moreira, A.L., Ladanyi, M., Kris, M.G., dkk., 2012. Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. *Molecular Cancer Therapeutics*, **11**: 2535–2540.
- Park, K., Tan, E.-H., O’Byrne, K., Zhang, L., Boyer, M., Mok, T., dkk., 2016. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *The Lancet Oncology*, **17**: 577–589.
- Patrikus, 2017. Studi Efektivitas Biaya Gefitinib dan Erlotinib pada Pasien NSCLC di RSUD DR Soetomo Surabaya. Thesis
- Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., dkk., 2017. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. *Annals of Oncology*, **28**: 270–277.
- Peraturan Presiden RI., 2013. *Jaminan Kesehatan Nasional*. Presiden Republik Indonesia, Jakarta.



- Peraturan Menteri Kesehatan RI., 2017. *Pedoman Penilaian Teknologi Kesehatan (Health Technology Assessment) dalam Program Jaminan Kesehatan Nasional*. Menteri Kesehatan RI, Jakarta.
- Purba, F.D., Hunfeld, J.A.M., Iskandarsyah, A., Fitriana, T.S., Sadarjoen, S.S., Ramos-Goñi, J.M., dkk., 2017. The Indonesian EQ-5D-5L Value Set. *PharmacoEconomics*, **35**: 1153–1165.
- Rascati, K.L., 2009, *Essentials of pharmacoeconomics*, Wolters kluwer, Lippincott Williams and wilkins, London, pp:1-222
- Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., dkk., 2009. Screening for epidermal growth factor receptor mutations in lung cancer. *The New England Journal of Medicine*, **361**: 958–967.
- Rossi, S., D'Argento, E., Basso, M., Strippoli, A., Dadduzio, V., Cerchiaro, E., dkk., 2016. Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. *Molecular Diagnosis & Therapy*, **20**: 55–63.
- Sari, S., Andayani, T.M., Endarti, D., dan Widayati, K., 2019. Efikasi Afatinib dan Gefitinib pada Pasien Non-small Cell Lung Cancer EGFR Mutasi Positif: Tinjauan Sistematis. *Indonesian Journal of Clinical Pharmacy*, **8**: 289.
- Schancez, L.A., 2008, *Pharmacoeconomics: Principles, Methods and Applications in DiPiro, JT., talbert,RL., Yee, Gary C., Matzke,GR., Wells,BG.,Posey,LM.: Pharmacoterapy: A Pathophysiologic Approach 7th edition, Mcgraw-Hill, New York, USA, pp: 1-2*
- Sequist, L.V., Yang, J.C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., dkk., 2013. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **31**: 3327–3334.
- Setiawan, D., Endarti, D., dan Suwantika, A.A., 2017. *Modeling Pharmacoeconomics*. UM Purwokerto Press.
- Sharma, V., Gaye, P.M., Wahab, S.A., Ndlovu, N., Ngoma, T., Vanderpuye, V., dkk., 2008. Patterns of Practice of Palliative Radiotherapy in Africa, Part 1: Bone and Brain Metastases. *International Journal of Radiation Oncology*Biophysics*Physics*, **70**: 1195–1201.
- Shi, Q., Guan, M., Wang, Y., Xu, C., Tang, L., Fu, W., dkk., 2018. Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine



- kinase inhibitor (TKI) treatment: A multi-center retrospective study: Survival analysis after TKI treatment. *Thoracic Cancer*, **9**: 278–283.
- Shi, Y., Li, J., Zhang, S., Wang, M., Yang, S., Li, N., dkk., 2015. Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study. *PLOS ONE*, **10**: e0143515.
- Sholl LM, Cagle PT, Lindeman NI., 2016. Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung; Version: LungBiomarkers 1.3.0.0: *College of American Pathologists*; Available at: <http://www.cap.org>.
- Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., dkk., 2012. Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker. *Journal of Pharmacology and Experimental Therapeutics*, **343**: 342–350.
- Temel, J.S., Gallagher, E.R., Jackson, V.A., Blinderman, C.D., dan Billings, J.A., 2010. Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer. *The New England Journal of Medicine*, **10**.
- Tillman, S.B., 2006. 'Overruling INS v. Chadha: Advice on Choreography - A Reply to Professor Sanford V. Levinson', , *SSRN Scholarly Paper*, . Social Science Research Network, Rochester, NY.
- Ting, J., Tien Ho, P., Xiang, P., Sugay, A., Abdel-Sattar, M., dan Wilson, L., 2015. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States. *Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research*, **18**: 774–782.
- Travis, W.D., Brambilla, E., Nicholson, A.G., Yatabe, Y., Austin, J.H.M., Beasley, M.B., dkk., 2015. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*, **10**: 1243–1260.
- Urata, Y., Katakami, N., Morita, S., Kaji, R., Yoshioka, H., Seto, T., dkk., 2016. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. *Journal of Clinical Oncology*, **34**: 3248–3257.



- van der Linden, N., Bongers, M.L., Coupé, V.M.H., Smit, E.F., Groen, H.J.M., Welling, A., dkk., 2016. Costs of non-small cell lung cancer in the Netherlands. *Lung Cancer*, **91**: 79–88.
- Vergnenegre, A., Borget, I., dan Chouaid, C., 2013. Treatment of lung cancer: will financial issues become a criterion of choice? *Expert Review of Pharmacoeconomics & Outcomes Research*, **13**: 273–275.
- Vyas, P., 2017. A Case Study and Literature Review: Adenocarcinoma of the Lung. *Cancer therapy & Oncology International Journal*, .
- Vogenberg FR., 2001. *Introduction to Applied Pharmacoeconomics*. McGraw-Hill, United Stated of America.
- Walley, T., Haycox, A., Boland, A., 2004, *Pharmachoeconomics*, 1-11, Churchill Livingstone, London
- Walker, M.S., Wong, W., Ravelo, A., Miller, P.J.E., dan Schwartzberg, L.S., 2017. Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study. *Health and Quality of Life Outcomes*, **15**: .
- Wang, H., Zeng, C., Li, Xin, Wang, Y., Li, Xinyi, dan Ge, W., 2019. Cost-utility of afatinib and gefitinib as first-line treatment for *EGFR* -mutated advanced non-small-cell lung cancer. *Future Oncology*, **15**: 181–191.
- Warth, A., Muley, T., Meister, M., Stenzinger, A., Thomas, M., Schirmacher, P., dkk., 2012. The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival. *Journal of Clinical Oncology*, **30**: 1438–1446.
- WHO., 2005, *Guidelines for Estimating the Economic Burden of Diarrhoeal Disease, with Focus on Assessing the Costs of Rotavirus Diarrhoea*
- Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., dkk., 2014. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *The Lancet Oncology*, **15**: 213–222.
- Xu, J., Liu, X., Yang, S., Zhang, X., dan Shi, Y., 2017. Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study. *OncoTargets and Therapy*, **Volume 10**: 4989–4995.



- Yang, S.-C., Lai, W.-W., Hsu, J.C., Su, W.-C., dan Wang, J.-D., 2020. Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan. *PLOS ONE*, **15**: e0231413.
- Yap, T.A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., dkk., 2010. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **28**: 3965–3972.
- Yu, H.A., Arcila, M.E., Rekhtman, N., Sima, C.S., Zakowski, M.F., Pao, W., dkk., 2013. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, **19**: 2240–2247.
- Zhao, Z.-M., Pan, X.-F., Lv, S.-H., Xie, Y., Zhang, S.-K., Qiao, Y.-L., dkk., 2014. Quality of life in women with cervical precursor lesions and cancer: a prospective, 6-month, hospital-based study in China. *Chinese Journal of Cancer*, .
- ZHENG, L., LIN, B., SONG, Z., XIE, F., HONG, W., FENG, J., dkk., 2013. Relationship Between BIM Gene Polymorphism and Therapeutic Efficacy in the Retreatment of Advanced Non-small Cell Lung Cancer with Tyrosine Kinase Inhibitor. *Chinese Journal of Lung Cancer*, **16**: 632–638.
- Zhu, J., Ye, M., Fu, J., Wu, B., Chu, Y., Zhao, Y., dkk., 2017. Cost-Effectiveness of Afatinib, Gefitinib, Erlotinib, and Pemetrexed-Based Chemotherapy as First-Line Treatments for Egfr Mutation Positive, Advanced Non-Small Cell Lung Cancer in China. *Value in Health*, **20**: A440–A441.